Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 6,560 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Grade III Lymphomatoid Granulomatosis, Adult Langerhans Cell Histiocytosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Mast Cell Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid/NK-cell Acute Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Anemia, Refractory Multiple Myeloma, Secondary Acute Myeloid Leukemia, Secondary Myelofibrosis, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Waldenstrom Macroglobulinemia
Interventions
deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Liver Biopsy
Interventions
biopsy
Diagnostic Test
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Type II Diabetes
Interventions
Best-Worst Scaling (Case 2), Discrete Choice Experiment
Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
1,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Cytomegalovirus Cell Mediated Immunity, Hematopoietic Cell Transplant
Interventions
Hematopoietic Cell Transplant, Letermovir
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Respiratory Failure, Intubation Complication
Interventions
intravenous crystalloid fluid, 500 mL
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Birmingham, Alabama • Jefferson, Louisiana • New Orleans, Louisiana + 4 more
Conditions
Epstein-Barr Virus Infection
Interventions
mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
482 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
34
States / cities
Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Disrupting SRFOH to Improve Substance Use and Mental Health Outcomes for Parents in Rural Regions

NCT06560866
Conditions
Substance-Related Disorders
Interventions
Just Care for Families
Behavioral
Lead sponsor
Chestnut Health Systems
Other
Eligibility
Not listed
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Eugene, Oregon
Conditions
Ulcerative Colitis, Digestive System Diseases, Colitis, Ulcerative, Colitis, Gastrointestinal Diseases, Inflammatory Bowel Diseases, Intestinal Diseases, Colonic Diseases, Autoimmune Disease, Abdominal Pain
Interventions
KHK4083, Placebo
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Greenville, South Carolina
Completed Not applicable Interventional Accepts healthy volunteers Results available

Case Selection and Treatment Protocol for Immediate Dental Implants in the Esthetic Zone

NCT02154581
Conditions
Jaw, Edentulous, Partially, Acquired Absence of Single Tooth
Interventions
SLActive implant
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Tendinopathy
Interventions
Isometric Exercise, Sham Transcutaneous Electrical Nerve Stimulation
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 28 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
Interventions
Iomab-B, Conventional Care, HCT
Drug · Procedure
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Gilbert, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 18 more
Conditions
Pancreatic Adenocarcinoma Metastatic
Interventions
OMTX705, Nab-paclitaxel + Gemcitabine, Tislelizumab (i.v. 200mg)
Drug
Lead sponsor
Oncomatryx Biopharma S.L.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chronic Kidney Disease, Congenital Anomalies of Kidney and Urinary Tract
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Meridian, Idaho • Neptune City, New Jersey + 2 more
Completed Not applicable Interventional Results available

Suicide Prevention for Justice Involved Managed Care Subscribers

NCT05579600
Conditions
Suicide and Self-harm
Interventions
Caring Contacts letters
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
45,155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Peripheral Nerve Blocks
Interventions
Peripheral Nerve Blocks with CAIG
Device
Lead sponsor
Clear Guide Medical
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Camden, New Jersey
Conditions
Adolescent Behavior, Psychosocial Functioning, Coping Behavior, Help-Seeking Behavior, Utilization, Health Care, Depression, Anxiety, Stress Disorders, Post-Traumatic, Emotion Regulation, Child Welfare
Interventions
Stronger Youth Networks and Coping (SYNC)
Behavioral
Lead sponsor
Portland State University
Other
Eligibility
16 Years to 20 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Post Operative Surgical Site Infection
Interventions
Standard of care, Vancomycin and Tobramycin
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
31
States / cities
Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
Conditions
Insulin-like Growth Factor-1 Deficiency
Interventions
NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Drug
Lead sponsor
Ipsen
Industry
Eligibility
5 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Brisbane, California
Completed No phase listed Observational Results available

Pivotal Study for Validation of Philips Dx (PDx)

NCT02529137
Conditions
Pathologic Processes
Interventions
Not listed
Lead sponsor
Philips Digital & Computational Pathology
Industry
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Silver Spring, Maryland • Cleveland, Ohio • Irving, Texas + 1 more
Conditions
Peripheral Arterial Disease, Cardiovascular Disease, Peripheral Vascular Disease
Interventions
Paclitaxel administration using the OPC
Other
Lead sponsor
Horizons International Peripheral Group
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
17
States / cities
Fairhope, Alabama • Jacksonville, Florida • Pensacola, Florida + 13 more
Conditions
Insomnia, Sleeplessness
Interventions
Wholetones Music, Classical Music
Behavioral
Lead sponsor
Jacksonville University
Other
Eligibility
25 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Jacksonville, Florida
Completed Not applicable Interventional Results available

Low-Level Laser Therapy for Plantar Fasciitis

NCT05763381
Conditions
Plantar Fascitis
Interventions
Photobiomodulation Therapy (PBMT), Sham-Photobiomodualtion Therapy (Sham-PBMT)
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Conditions
HIV Testing
Interventions
Intervention, Enhanced Standard of Care, Traditional Standard of Care
Behavioral
Lead sponsor
City University of New York, School of Public Health
Other
Eligibility
18 Years and older
Enrollment
4,458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers

Stress and Recovery in Frontline COVID-19 Workers

NCT04713111
Conditions
Covid19, Stress, Wearables
Interventions
Lifestyle (Meditation), Lifestyle (Exercise)
Behavioral
Lead sponsor
4YouandMe
Other
Eligibility
18 Years and older
Enrollment
383 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Seattle, Washington